Do bone density, bone microarchitecture and body composition differ in recipients of allogeneic haematopoietic stem cell transplant? A cross-sectional study from southern India
The evolution of Allogeneic Haematopoietic Stem Cell Transplant (allo-HSCT) as a treatment modality has witnessed the cure of several haematological conditions such as leukaemia, lymphoma, multiple myeloma, myelodysplastic syndromes, thalassaemia and aplastic anaemia [1]. The many advances made in this domain, and the availability of excellent post transplant care have ensured increased longevity in recipients of allo-HSCT. It has been demonstrated in previous studies that patients who are disease-free at five years after HSCT have a 10-year survival rate that exceeds 80% [2].
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Kripa Elizabeth Cherian, Nitin Kapoor, Anup J. Devasia, Vikram Mathews, Alok Srivastava, Nihal Thomas, Biju George, Thomas V. Paul Source Type: research
More News: Anemia | Aplastic Anemia | Biology | Hematology | India Health | Leukemia | Lymphoma | Myelodysplastic Syndrome | Myeloma | Stem Cell Therapy | Stem Cells | Study | Transplants